苯作业工人白细胞降低者的总估校正现患率

选择乡镇工业苯作业工人４次外周血白细胞计数中的间隔半年的两次数据，应用俘获再俘获法，计算其白细胞降低者的总估校正现患率（ＡＣＰＲ）。结果苯接触组为３６．８ｌ％（２９．１４％～４４．４８％），对照组为１２．７１％（７．２０％～１８．２２％）具有显著差异，其相对危险度为２，９。用常规法求得的４次检出率分别是：苯接触组为２６．３７％，１８．７３％，２７．９３％，３６．７６％；对照组为６。８５％，７．３８％，７．９４％，１５．００％。均在其ＡＣＰＲ之９５％可信限内，可见ＡＣＰＲ计算方法简便、结果准确，值得推广。对于稳定的人群，可用其每年一次的健康监护资料计算ＡＣＰＲ。     

Inhibition of rat heart allograft rejection by a PUVA treatment of the graft recipient

Treatment of rat heart grafts with PUVA, the combination of the photosensitizer 8-methoxypsoralen and longwave ultraviolet light, leads to a prolonged transplant survival in allogeneic recipients. A PUVA treatment of the recipient rats, performed for 7 consecutive days after transplantation, prolonged graft survival even more effectively. This may be due to the systemic immunomodulatory effects of PUVA in the recipient. One of the mediators is urocanic acid, which is transformed by ultraviolet light in the skin from its trans- to the cis-isomer, which, in turn, acts as a mediator on the immune system. An injection of cisurocanic acid into graft recipients for 7 consecutive days after transplantation resulted in prolonged graft survival; in 40% of the rats, permanent graft acceptance was observed. The significance of these results for clinical organ transplantation is discussed.     

The chronotropic effect of acetylcholine in the presence of vecuronium and atracurium A study in the isolated perfused rabbit heart

The bradycardia produced by 1 microgram acetylcholine in the isolated perfused rabbit heart, in the presence of vecuronium and atracurium, was studied and compared with control. Vecuronium at a concentration of 2.5 micrograms/litre and atracurium 6 micrograms/litre did not enhance the negative chronotropic effect of acetylcholine. Atracurium produced a statistically significant inhibition of the negative chronotropic effect of acetylcholine.     

MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients

Little is known about biological predictors of treatment response in panic disorder (PD). In the present study heart rate, blood pressure, plasma cortisol and plasma MHPG were investigated at baseline in a sample of 44 PD patients as possible predictors for nonresponse to treatment. We used a strict definition of nonresponse to find patients who did not respond at all after 12 weeks of treatment with brofaromine or fluvoxamine. Patients were considered nonresponders when they fulfilled two criteria: they did not show a 50% reduction of agoraphobic avoidance and they still experienced panic attacks at endpoint. The variables that differed significantly between the groups were used to predict nonresponse to drug therapy. Using this strict definition of nonresponse, 15 patients (32.6%) were considered nonresponders. These patients were characterised by a higher plasma MHPG concentration and a higher heart rate at baseline. These variables were subsequently used to predict nonresponse.     

低温保存同种心脏瓣膜活性及临床应用的研究

取正常成人心脏瓣膜３６个，置于低浓度广谱抗生素的营养液（ＲＰ－ＭＩ１６４０细胞培养液）中灭菌４８ｈ，－８０℃冰箱初冻，置于液氮中长期保存。灭菌前后瓣膜细菌培养阴性率分别为９４．３％和１００％，解冻后经光镜、电镜检查证实瓣组织细胞结构正常，组织培养葡萄糖消耗率测定示瓣组织存活良好。临床同种心脏瓣膜原位移植３例，随访６～３０个月，瓣功能良好     

测定血清及尿β2微球蛋白评估健康老年人肾功能的价值

测定72例健康老年人（60-84岁）和65例健康青中年人（20-50岁）血清和尿β2微球蛋白（β2m)，发现前血清β2m浓度比后明显增高（p<0.001)；老年组≥70岁尿液β2m浓度也明显增高（p<0.05)。结果表明肾小球滤过率下降随年龄增长而降低，以后再出现肾小管功能减退。本试验较血清尿素氮、肌酐和内生肌酐清除率测定更为敏感。     

β受体阻滞在心血管疾病中的临床应用研究进展

依据国内外的临床研究和循证医学分析,对β受体阻滞剂在心血管疾病方面的合理应用以及适应证,给药方法进行循证性举证,提示β受体阻滞剂可明显改善心血管疾病的临床预后,除非有禁忌证及不能酎受者,β受体阻滞剂应作为心血管疾病的常规治疗病物广泛应用于心血管疾病。     

山莨菪碱对梗阻性黄疸心脏的保护作用

目的 观察梗阻性黄疸时山莨菪碱对心脏的保护作用。方法将30只成年Wistar大鼠随机分为假手术组和梗阻性黄疸模型组;模型组包括山莨菪碱治疗组,生理盐水对照组。分别于术后第14、28天测定各组血浆内毒素含量,观察心肌病理、酶组织化学和心率改变及山莨菪碱治疗后的变化。结果生理盐水对照组血浆内毒素水平明显升高,心肌出现变性、局灶坏死、线粒体破损等病理改变,心肌组织琥珀酸脱氢酶、腺苷三磷酸酶活性明显降低(P<0.05),而酸性磷酸酶活性明显增强(P<0.05),心率明显减缓(P<0.05),山莨菪碱治疗组则以上情况均有明显改善(P>0.05)。结论 山莨菪碱对梗阻性黄疸时心脏有保护作用。     

MRI的选购定位

对MRI若干主要参数进行总结,结合实际应用体会,对我院MRI设备选购进行讨论,以期对MRI设备的选购定位提供参考.     

1 108例终末期肾脏疾病血液透析病人原发疾病构成及相关因素分析

目的 回顾性研究终末期肾脏疾病（end stage renal disease，ESRD）血液透析病人原发疾病构成及其相关因素。方法 收集ESRD血液透析病人1108例，分析其原发疾病构成、年龄、性别、透析治疗持续时间、转归、生存率和死亡原因。结果 301例病人透析时间超过3个月，其中43．9％仍在进行血液透析治疗，最长者已存活13年；13．0％病人已行肾脏移植；19．9％转至外院治疗；7．3％改为腹膜透析；1．3％因经济困难放弃治疗；14．6％病人死亡。ESRD维持性血液透析病人1年生存率为93．53％，3年生存率为68．92％。5年生存率62．51％。死亡原因为心血管事件占54．5％，脑血管意外占20．5％。结论 本组病人以中、老年为主，男性多见。ESRD血液透析病人主要原发疾病为慢性肾小球肾炎，主要死亡原因为心血管事件和脑血管意外。